Bullous pemphigoid‐like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab
Authors:
- 15 November 2016
- journal article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 57 (4) , 333-335
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumabMelanoma Research, 2015
- Managing Immune Checkpoint-Blocking Antibody Side EffectsAmerican Society of Clinical Oncology Educational Book, 2015
- Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 TherapyCancer Immunology Research, 2015
- Ipilimumab in patients with cancer and the management of dermatologic adverse eventsJournal of the American Academy of Dermatology, 2014
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)Cancer, 2007